U.S. License Holder:
Alexion Pharm.
Date of License:
December-21-2018
Last Update:
February-28-2021
FDA-Approved Indications
ULTOMIRIS (ravulizumab-cwvz) is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH);
The treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (™A).